LPTX - リ―プ・セラピュ―ティクス （LEAP THERAPEUTICS INC.）

Leap Therapeutics, Inc. (NASDAQ:LPTX – Get Rating) – Equities research analysts at HC Wainwright decreased their FY2023 EPS estimates for Leap Therapeutics in a research note issued on Monday, March 27th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.20) for the year, down from their prior […]

Leap Therapeutics press release (LPTX): Q4 GAAP EPS of -$0.11 in-line.Cash and cash equivalents totaled $65.5 million at December 31, 2022, which excludes the approximately $50…

CAMBRIDGE, Mass., March 24, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2022. Leap Highlights:…

Leap Therapeutics Inc (NASDAQ: LPTX ) announced BeiGene Ltd''s (NASDAQ: BGNE ) option under the Exclusive Option, and License Agreement granting rights in certain Asian territories to DKN-01 has expired . The companies announced an option agreement in January 2020 for DKN-01 in Asia (excluding Japan), Australia, and New Zealand. Leap and BeiGene will continue collaborating on Part C of the DisTinGuish trial, a … Full story available on Benzinga.com

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Morning Sizzling Stocks Alert: Greenidge Generation Holdings Inc. (NASDAQ:GREE), Leap Therapeutics, Inc. (NASDAQ:LPTX) appeared first on Stocks Equity .

Leap Therapeutics Inc. (NASDAQ:LPTX) price on Friday, March 25, fall -2.79% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.74. A look at the stock’s price movement, the close in the last trading session was $1.79, moving within a range at $1.71 and $1.795. The beta value … What Can Leap Therapeutics Inc. (NASDAQ: LPTX) Expect In 2022? Read More »

Leap Therapeutics (NASDAQ: LPTX ) reported its Q4 earnings results on Friday, March 11, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Leap Therapeutics beat estimated earnings by 9.09%, reporting an EPS of … Full story available on Benzinga.com

Leap Therapeutics press release (LPTX): Q4 GAAP EPS of -$0.10 beats by $0.01.Revenue of $0.38M (flat Y/Y) beats by $0.08M.CEO comment: "Following our public offering, we are well…

CAMBRIDGE, Mass., March 11, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2021. Leap Highlights:…

CAMBRIDGE, Mass., March 2, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer will present a corporate overview at…

Leap Therapeutics Inc. (NASDAQ:LPTX) price on Friday, March 25, fall -2.79% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.74. A look at the stock’s price movement, the close in the last trading session was $1.79, moving within a range at $1.71 and $1.795. The beta value … What Can Leap Therapeutics Inc. (NASDAQ: LPTX) Expect In 2022? Read More »

Leap Therapeutics (NASDAQ: LPTX ) reported its Q4 earnings results on Friday, March 11, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Leap Therapeutics beat estimated earnings by 9.09%, reporting an EPS of … Full story available on Benzinga.com

Leap Therapeutics press release (LPTX): Q4 GAAP EPS of -$0.10 beats by $0.01.Revenue of $0.38M (flat Y/Y) beats by $0.08M.CEO comment: "Following our public offering, we are well…

CAMBRIDGE, Mass., March 11, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2021. Leap Highlights:…

CAMBRIDGE, Mass., March 2, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer will present a corporate overview at…